Close

TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at AAN

April 24, 2018 8:07 AM EDT Send to a Friend
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login